| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Department of Molecular Biology, Princeton University, Princeton, New Jersey
Requests for reprints: Jean E. Schwarzbauer, Princeton University, Department of Molecular Biology, Washington Road, Princeton, NJ 08544-1014. Phone: 609-258-2893; Fax: 609-258-1035; E-mail: jschwarz{at}princeton.edu.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The ECM governs a wide variety of cellular processes, including proliferation, differentiation, and migration, and changes in the ECM microenvironment occur during both developmental and disease processes (6, 7). The mammary gland provides an excellent example of these changes, as ECM composition is modulated during development (8) and oncogenesis (9). The normal mammary gland consists of a series of branching ducts, each branch ending with an acinus, which has a hollow, sphere-like structure and is the functional unit of the mammary gland responsible for milk secretion. Each acinus is composed of a single layer of polarized mammary epithelial cells surrounded by a basement membrane of collagens I, III, and IV, laminin, and heparan sulfate proteoglycans (10).
Mammary gland development and breast oncogenesis are accompanied by dramatic alterations in the composition, architecture, and mechanical properties of the ECM. During development, as branching morphogenesis occurs, levels of fibronectin, laminin, and collagen I increase, with fibronectin showing the most dramatic changes (8). Epithelial cell–associated fibronectin also increases as the mammary gland prepares for lactation (8). During oncogenesis, the basement membrane is not maintained and its components are distributed throughout the tumor stroma (9). Compositionally, there are changes in deposition of certain matrix proteins within tumors, including elastin, tenascin-C, osteopontin, collagen III, and fibronectin (11–14). Mechanically, these alterations to the matrix result in an increase in the rigidity of the mammary tissue to levels capable of perturbing the morphology and proliferative state of mammary epithelial cells in vitro (15, 16). The signals responsible for these changes in ECM composition, as well as subsequent cellular responses, are an area of active research.
In normal adult mammary tissue, interstitial ECM is largely devoid of fibronectin (14) and the tissue is soft and pliable (15). However, increased fibronectin levels have been observed in the stroma of benign hyperplasias and various types of mammary tumors (13, 14) and established tumor tissue has a stiffness that is an order of magnitude higher than normal tissue (17). Histologic data are supported by reverse transcriptase–PCR (RT-PCR) and microarray analyses of transcript levels showing an up-regulation of fibronectin associated with primary malignancies (12, 18). This matrix abnormality seems to affect disease outcome, as high fibronectin and β1 integrin levels in tumor sections correlate with decreased survival of breast cancer patients (19). These studies provide circumstantial evidence for a role for fibronectin in the development and/or progression of mammary tumorigenesis. However, the mechanisms by which fibronectin expression is controlled and its molecular contributions to the early stages of breast cancer pathology have yet to be uncovered.
To address this issue, we are using a well-established culture system, in which mammary epithelial cells are induced to differentiate on a three-dimensional Matrigel reconstituted basement membrane matrix (20). Morphogenesis of nontumorigenic MCF-10A cells on this matrix recapitulates an acinar morphology similar to normal mammary tissue (Fig. 1A ). In early, proliferative stages of differentiation, single cells grow into multicellular clusters and initiate secretion of basement membrane components, such as type IV collagen and laminin-5 (20, 21). Subsequently, the outer layer of cells becomes polarized to the basement membrane and cell growth is arrested. The interior cells then undergo apoptosis resulting in a hollow acinus (22, 23). Thus, well-developed acini are characterized by a hollow lumen surrounded by a single layer of growth-arrested cells.
|
0.15 kPa) to pathologic levels found in tumors (
4.0 kPa) prevented mammary epithelial cells from forming acini (17). We show here that fibronectin expression is modulated by matrix composition and rigidity during acinar morphogenesis and that excess fibronectin affects the proliferative state of MCF-10A cells in acinar cultures with significant effects on acinar size. | Materials and Methods |
|---|
|
|
|---|
Three-dimensional basement membrane culture. Morphogenesis assays were conducted as previously described (20), except cells were plated at 2,500 per well in eight-well Nunc chamber slides. Rat plasma fibronectin in CAPS buffer [10 mmol/L CAPS (pH 11), 150 mmol/L NaCl] was added to either culture medium (at 50–100 µg/mL) or Matrigel matrix (at 25 µg/mL). Control cultures received the equivalent amount of CAPS buffer. Assay medium is 2% horse serum, which contributes
0.6 µg fibronectin/mL of medium. Rat plasma fibronectin was purified from rat plasma (Taconic) by gelatin-Sepharose affinity chromatography as previously described (26).
Immunofluorescence microscopy. Immunofluorescence staining of acini was done as previously described by Debnath et al. (20). Visualization was done using a Nikon TE2000U microscope equipped with a Cooke SensiCamQE High-Performance Camera and CARV spinning-disc confocal (Atto Biosciences). Images were acquired and managed using IPLab software. Fibronectin levels in acini were determined by measuring the average fluorescence intensity per pixel along both the x and y diameters of the widest confocal cross-section of each antifibronectin-stained acinus using unmodified images captured with equal exposure times.
Primary antibodies include antihuman fibronectin HFN 7.1 culture supernatant at 1:500 (Developmental Studies Hybridoma Bank) and anti–Ki-67 at 1:150 (Zymed). HFN7.1 is species-specific and does not recognize mouse fibronectin (27). Secondary Alexa Fluor goat anti-mouse and goat anti-rabbit antibodies (Molecular Probes) were used at 1:300. Other reagents include Alexa Fluor 488–conjugated phalloidin and rhodamine-phalloidin, both at 1:500 (Molecular Probes) and 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) at 0.75 µg/mL.
To assess acinar size and morphology, cultures were fixed and stained with DAPI, fluorescently conjugated phalloidin, and antibodies against Ki-67 as indicated. By confocal microscopy, the widest cross-section of each acinus was located and examined, excluding only those acini in direct contact with neighbors. In each cross-section, the total number of cells, the number of Ki-67 positive cells, the number of cells lining the circumference, and the number of cells in the interior were counted. Only nuclei clearly in the plane of focus were counted. A hollow acinus was defined as one lacking any nuclei in the interior of the structure. To visualize the size distribution of the population, acini were grouped by cell number into bins of four cells, the frequency of occurrence was graphed, and the distribution was fitted with a Gaussian curve. To determine the significance of size differences between acini grown on Matrigel (control) versus Matrigel with fibronectin, the average number of cells per acinus was calculated for the control and the percentage of acini with more cells than the control average was determined and graphed. The statistical significance of the percentages was determined using a t test of proportions (see Statistical analysis in Materials and Methods).
Metabolic labeling and quantification of fibronectin production. Cells were cultured for the indicated periods of time, in the absence or presence of excess fibronectin, at a concentration of 50 µg/mL and labeled with 100 µCi [35S]methionine (MP Biomedicals)/mL of medium for 24 h before collection of the medium and lysis of cells in modified RIPA buffer (28). Fibronectin was isolated from culture medium using gelatin-Sepharose binding (26). Isolated fibronectin was then reduced by addition of 0.1 mol/L DTT and separated by SDS-PAGE. Gels were dried, placed on a phosphor storage screen and bands detected and quantified using a Storm 860 system (GE Healthcare Life Sciences). Samples were normalized before loading using results from a β-N-acetylglucosaminidase activity assay (Sigma) performed on cell lysates.
Polyacrylamide substrates. Polyacrylamide substrates were made as previously described (29, 30). Briefly, polyacrylamide gels were polymerized on aminosilanized glass coverslips. To modulate the stiffness of the gel, the acrylamide to cross-linker N,N'methylene-bis-acylamide ratio was varied as follows: 3% to 0.06% acrylamide/bis-acrylamide for 0.3 kPa, 4% to 0.15% acrylamide/bis-acrylamide for 3.5 kPa, and 10% to 0.3% acrylamide/bis-acrylamide for 34 kPa. Laminin-1 (kindly provided by Dr. Peter Yurchenco, Robert Wood Johnson Medical School) or fibronectin were attached to the gel surfaces using a photo-activated bifunctional cross-linker sulfo-SANPAH (Pierce) and 10 µg/mL protein solutions in 50 mmol/L HEPES (pH 8.5).
Cells were plated in assay medium on polyacrylamide gels with different elastic moduli at 12 x 104 cells per well in a 24-well dish for 24 h, at which time gels were transferred to new wells and metabolic labeling was done as described above.
Real-time RT-PCR. MCF-10A cells were plated in wells of a 24-well dish at 12 x 104 cells per well with or without Matrigel substrate or on polyacrylamide gels coated with laminin-1 or fibronectin. Cells were cultured for 48 h and RNA was then prepared using Trizol reagent (Invitrogen) according to the manufacturer's instructions, including an additional 10-min postlysis spin at 4°C to remove excess Matrigel if necessary. cDNA was prepared, and real-time PCR was performed as described elsewhere (31). Parallel PCR reactions were performed with ubiquitin C primers as a normalization control (32). All samples were run in triplicate using fibronectin primers from separate exons to eliminate potential contributions from genomic DNA: 5'-AAACTTGCATCTGGAGGCAAACCC-3' (forward) and 5'-AGCTCTGATCAGCATGGACCACTT-3' (reverse). Data were analyzed using SDS 2.1 software (Applied Biosystems).
Statistical analyses. Statistics were performed, and P values were calculated using a standard t test or a t test of proportions as appropriate. P values of <0.05 were considered significant. On all graphs, an asterisk (*) indicates that the difference between the control and treatment data is statistically significant. Graphs representing the percentage above the average of Matrigel control do not have error bars; however, the difference between them is statistically significant as determined above.
| Results |
|---|
|
|
|---|
Fibronectin stimulates overproliferation and increases acinar size. Fibronectin is known to promote cell growth, so its down-regulation may be linked to the switch from proliferation to growth arrest as mammary epithelial cells differentiate. To test the effect of fibronectin on proliferation, high fibronectin levels were maintained by inclusion of excess rat fibronectin in the Matrigel matrix during differentiation. Proliferation of MCF-10A cells cultured with and without excess fibronectin was monitored during the initial proliferative phase of morphogenesis. Staining for expression of Ki-67, a nuclear antigen expressed from late G1-M phase of the cell cycle, is a reliable indicator of cell cycle progression routinely used in this culture system (22, 33–35). Cells were costained with DAPI, and the percentage of Ki-67–positive cells in the widest confocal cross-section of each acinus was calculated (Supplementary Fig. S1A). Most of the cells were positive for Ki-67 during the first few days on Matrigel and on Matrigel with excess fibronectin (day 1; Fig. 2A
). However, the continuous presence of fibronectin maintained a significantly higher percentage of Ki-67–positive cells during days 4 to 7 compared with those grown on Matrigel matrix alone (Fig. 2A). The increased number of proliferating cells with excess fibronectin persisted throughout the growth phase, but the difference was negligible by day 9 with the onset of growth arrest. Cell shapes were indistinguishable on Matrigel with and without fibronectin. Immunofluorescence staining with anti-
5β1 integrin antibodies showed obvious basolateral staining of acini with and without fibronectin at 6 and 11 days of acinar development (data not shown).
|
|
|
|
5β1 integrin levels were found in either early-stage or late-stage acini by fluorescence-activated cell sorting (FACS) or immunofluorescence, respectively (data not shown). These results show that continuous inclusion of fibronectin with Matrigel increases the amount of fibronectin matrix deposited within acini during MCF-10A differentiation.
Fibronectin expression is regulated by substrate composition and rigidity. During tumor formation in the breast, changes in tissue architecture and matrix composition are accompanied by increases in tissue rigidity. Relative to tissue culture plastic where MCF-10A fibronectin transcript levels were high, Matrigel is soft and fibronectin transcript levels were reduced by almost 6-fold (see Fig. 1C). In addition, fibronectin is the major ECM protein when MCF-10A cells are cultured on plastic, whereas Matrigel provides a laminin-rich environment. To distinguish between the effects of ECM composition and rigidity, we used substrates of fibronectin or laminin-1 cross-linked to synthetic polyacrylamide gels of varying rigidity. Polyacrylamide gels were prepared with elastic moduli of 0.3 and 3.5 kPa, similar to Matrigel or normal mammary tissue and to mammary tumors, respectively (17). Gels at 34 kPa were used as a rigid control. The amount of 35S-labeled fibronectin produced between 24 and 48 hours after plating was monitored. At 34 kPa, fibronectin production was reduced on the laminin-1 substrate compared with the fibronectin-coated gel (Fig. 5A and B
), indicating that laminin-1, an abundant component of Matrigel, contributes to fibronectin down-regulation. Substrate rigidity also plays a role because cells on the 3.5-kPa gel produced less fibronectin than cells at 34 kPa. Interestingly, at 3.5 kPa, production of fibronectin by cells on laminin-1 was again lower than that by cells on fibronectin cross-linked gels (Fig. 5A and B). Cells produced similar low amounts of fibronectin when plated on the softest 0.3-kPa substrate, whether it was cross-linked with fibronectin or laminin-1. Overall, the differences between fibronectin levels on soft 0.3 kPa versus stiff 34 kPa substrates were 1.7-fold on laminin-1 and 2.5-fold on fibronectin (Fig. 5B). Fibronectin mRNA levels determined by qRT-PCR paralleled 35S-protein levels (Fig. 5C). Furthermore, there was no difference in cell morphology on fibronectin relative to laminin-1 substrates at the same elastic modulus, and FACS analyses showed no difference in
5β1 integrin levels after 48 hours on polyacrylamide substrates with fibronectin or laminin at any rigidity (data not shown). These results show that a soft substrate is sufficient to down-regulate fibronectin production by MCF-10A cells. With increased matrix stiffness, contributions from the ECM, such as the presence of fibronectin, determine the level of fibronectin production.
|
| Discussion |
|---|
|
|
|---|
Previous work investigating the role of fibronectin in the mammary gland has correlated its expression with proliferation of epithelial cells. In vivo fibronectin and
5β1 expression and localization in epithelial cells of the intact gland correlate with periods of cell growth (8). Additionally, expression of a transgenic dominant-negative β1 integrin disrupted mammary gland development by decreasing proliferation and increasing apoptosis (37). In vitro mammary epithelial cells have been shown to respond to regulatory hormones when plated on fibronectin but not on laminin (38). Our results show that, during the initial stages of acinar differentiation on Matrigel, excess fibronectin increased proliferation. Early growth stimulatory effects have been linked to expression of a variety of signaling molecules, including human papillomavirus (HPV) E7 oncoprotein, ErbB2, cyclin D, and activated Akt (22, 23, 33). Whereas HPV E7 and ErbB2 each induce sustained growth stimulation throughout morphogenesis, activated Akt, like fibronectin, has its primary proliferative effect in the early growth stage (23). Continuous activation of ErbB2 has a more dramatic effect than the others, causing significant overproliferation of MCF-10A cells into multiacinar structures with filled lumens (22, 33). Together, these results show the differential effects on acinar morphogenesis of signaling through growth factor receptors, cell cycle pathways, and cell adhesion and indicate that control of cell growth and growth arrest depends on the integration of multiple signals.
Signals from other matrix molecules are also essential because laminin-1 is needed to establish cell polarity and growth arrest (24). Laminin and laminin-binding integrins are well-known mediators of morphogenesis. Blocking β4 or β1 integrin function with antibodies perturbs acinar differentiation with effects including interruption of morphogenesis, inhibition of cell growth, and induction of apoptosis (21, 34). Certainly, some of these effects are due to loss of laminin binding; however, our results suggest a reduction of interactions between
5β1 and fibronectin by anti-β1 function-blocking antibodies may also contribute. The dynamic nature of fibronectin production and its regulation by exogenous fibronectin during morphogenesis may provide new insights into mammary differentiation, development, and cancer progression. It is also interesting to speculate on the role fibronectin plays in branching morphogenesis in the breast as it is highly associated with epithelial cells during that process, and fibronectin has already been identified as an early signal inducing branching morphogenesis in the salivary gland (39).
During tumorigenesis in the breast, primary tumors are characterized by increased deposition of fibronectin (12–14, 18, 19), increased tissue rigidity (17), loss of epithelial cell polarity, increased proliferation, and luminal filling (1). Our data show that addition of excess fibronectin to differentiated cultures resulted in a reversal of growth arrest and failure to maintain the acinar structure. The reinitiation of cell growth and luminal filling seen here seem analogous to the changes seen with the emergence of breast cancer in vivo. Therefore, fibronectin may serve a key mitogenic role for mammary epithelial cells and promote oncogenic progression by stimulating aberrant proliferation.
Our results point toward a mechanism by which stiffening of the matrix affects proper acinar morphogenesis by modulating fibronectin expression. Conditions closest to those found in the normal mammary gland, laminin-rich with a low elastic modulus, favored down-regulation of fibronectin gene transcription, resulting in reduced protein production. In contrast, conditions similar to those found in mammary tumors, fibronectin-rich with a high elastic modulus, favored up-regulation of fibronectin mRNA and protein levels. Previous work has shown that progressively increasing the stiffness of the matrix prevents cells from differentiating into acini (17). Small increases in rigidity (0.1–4 kPa) resulted in increased proliferation and failure to form a hollow lumen, a phenotype similar to that seen for acini in the presence of excess fibronectin where epithelial cells are expressing high levels of fibronectin. This phenocopy and the increased fibronectin production on substrates with elastic moduli above that of Matrigel and normal mammary tissue may indicate that fibronectin contributes to the aberrant cell behaviors noted on stiff substrates.
Thus, in our model for fibronectin function during acinar morphogenesis, MCF-10A cells initially express fibronectin during the growth phase of differentiation. Over time, signals from Matrigel, including laminin-1 and low substrate rigidity, induce down-regulation of fibronectin, such that levels are negligible in fully differentiated, growth-arrested acini. This pattern is similar to that found in vivo in both mammary gland and lung (8, 40). However, when the matrix is abnormal due to addition of exogenous fibronectin, a positive feedback loop is initiated, whereby fibronectin levels during the proliferative phase of morphogenesis are not reduced even after the onset of growth arrest, possibly contributing to the failure of acini in these circumstances to form a hollow lumen.
Modulation of fibronectin expression by tissue stiffness and the effects of increased fibronectin on cell growth may together have profound implications for breast cancer progression. It is understood that dense breast tissue, which is more rigid than normal tissue, is also prone to development of hyperplasias and dysplasias (16, 41). Should the altered stiffness of the mammary tissue promote increased fibronectin production by mammary epithelial cells, this would further stimulate proliferation. Indeed, a direct correlation was observed between mammographic density, deposition of the ECM proteoglycans lumican and decorin, and the presence of hyperplastic lesions (41). The propensity for hyperplastic growths to form in dense breast tissue may be in part due to increased deposition of fibronectin by mammary epithelial cells, which our results show can stimulate further fibronectin production and proliferation.
These data lend themselves to a model for the promotion of breast cancer progression by fibronectin (Supplementary Fig. S4). Oncogenic mutations in the mammary epithelium often result in a failure to maintain the basement membrane. This failure could then initiate a desmoplastic response, characterized by increased and aberrant deposition of ECM molecules (42) which would increase the elastic modulus of the tissue. Decreased contact with basement membrane laminin-1, increased contact with stromal fibronectin, and higher substrate rigidity may then stimulate mammary epithelial cells to produce their own fibronectin. Activation of this positive feedback loop would stimulate cell proliferation, leading to luminal filling and loss of normal tissue architecture. Thus, fibronectin may promote primary tumor formation by modifying the ECM to provide a substratum permissive for aberrant cell growth, thereby encouraging the acquisition of further oncogenic mutations.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Dr. Stella Karuri for valuable assistance in statistical analyses and Dr. Peter Yurchenco for supplying purified laminin-1.
The HFN 7.1 antibody developed by R.J. Klebe was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Resources and maintained by University of Iowa Department of Biological Sciences.
| Footnotes |
|---|
Received 7/13/07. Revised 1/22/08. Accepted 2/28/08.
| References |
|---|
|
|
|---|
(5)β(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 2001;142:3214–22.
5, and
-smooth muscle actin in heart and lung development. Am J Respir Cell Mol Biol 1992;6:472–80.[Medline]This article has been cited by other articles:
![]() |
J. A. Quinn, C. T. Graeber, A. R. Frackelton Jr., M. Kim, J. E. Schwarzbauer, and E. J. Filardo Coordinate Regulation of Estrogen-Mediated Fibronectin Matrix Assembly and Epidermal Growth Factor Receptor Transactivation by the G Protein-Coupled Receptor, GPR30 Mol. Endocrinol., July 1, 2009; 23(7): 1052 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Hansen, L. Kiemele, O. Maller, J. O'Brien, A. Shankar, J. Fornetti, and P. Schedin An In-solution Ultrasonication-assisted Digestion Method for Improved Extracellular Matrix Proteome Coverage Mol. Cell. Proteomics, July 1, 2009; 8(7): 1648 - 1657. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Engler, P. O. Humbert, B. Wehrle-Haller, and V. M. Weaver Multiscale Modeling of Form and Function Science, April 10, 2009; 324(5924): 208 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Han, J. D. Ritzenthaler, X. Sun, Y. Zheng, and J. Roman Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} Induces Lung Cancer Growth via Peroxisome Proliferator-Activated Receptor Coactivator {gamma}-1{alpha} Am. J. Respir. Cell Mol. Biol., March 1, 2009; 40(3): 325 - 331. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |